Polymyalgia rheumatica (PMR) is not directly inherited like a single-gene disorder, but genetics do play a meaningful role in who develops it. Specific immune-system genes increase susceptibility, and the condition clusters in populations with Northern European ancestry. However, no strong pattern of familial inheritance has been documented, meaning having a relative with PMR does not dramatically raise your personal risk the way it might with some other autoimmune conditions.
The Genetic Link: HLA Genes and PMR Risk
The strongest genetic connection to PMR involves a group of genes called HLA (human leukocyte antigen) that help your immune system distinguish your own tissue from foreign invaders. One variant in particular, HLA-DRB1*04, shows up in roughly 67% of PMR patients, a rate far higher than in the general population. This variant doesn’t cause PMR on its own, but it appears to prime the immune system in a way that makes the inflammatory response behind PMR more likely.
A large genome-wide association study using data from the UK Biobank and FinnGen confirmed HLA-DRB1 as the strongest genetic signal for PMR. The study also identified a second region, near the ANKRD55/IL6ST genes, that reached statistical significance. These genes are involved in immune signaling, which fits with what researchers understand about PMR as a disease of immune dysregulation. Still, carrying these variants is common in healthy people too, so they raise risk modestly rather than determining whether someone will develop the condition.
Other genetic variations linked to PMR affect molecules involved in inflammation and immune cell communication. Polymorphisms in genes related to a cell-adhesion molecule (ICAM-1), a chemical signal that attracts immune cells (RANTES), and receptors for a key inflammatory messenger (IL-1) have all been associated with PMR in certain populations. The picture that emerges is one of many small genetic nudges rather than a single inherited switch.
Does PMR Run in Families?
Despite the genetic associations, PMR does not show a clear pattern of running in families. A comprehensive literature review that specifically looked for familial clustering found no familial cases among PMR patients. By contrast, the closely related condition giant cell arteritis (GCA) did show familial grouping at about 1 in 83 cases, which is several times higher than what would be expected by chance. Brother-brother pairs, sisters, and mother-daughter pairs were identified with GCA, but nothing comparable turned up for PMR alone.
No twin studies have been published for PMR specifically, which means there is no heritability estimate (the percentage of disease risk attributable to genetics versus environment) available for this condition. That gap in the research makes it harder to quantify the genetic contribution precisely. For comparison, other autoimmune inflammatory conditions have heritability estimates ranging from about 40% to 70%, suggesting genetics matters but never tells the whole story.
Why Ancestry Matters
PMR is far more common in people of Northern European descent than in other populations. Annual incidence reaches up to 50 per 100,000 people over age 50 in Scandinavian countries, while the condition is uncommon in places like India. The highest rates cluster in Scandinavia and in Western and Eastern European regions historically settled by Norse populations. Researchers have noted that Viking migration patterns map surprisingly well onto the modern geography of PMR prevalence.
This population-level pattern reflects the higher frequency of PMR-associated HLA variants in Northern European gene pools. It does not mean that people of other backgrounds are immune to PMR, just that the baseline genetic susceptibility is lower. If you have Scandinavian or Northern European heritage, your background puts you in a higher-risk group statistically, though the absolute risk for any individual remains small.
Genetics Alone Is Not Enough
Autoimmune conditions broadly require two ingredients: a genetic predisposition and an environmental trigger. PMR follows this pattern. The immune-system gene variants associated with PMR are carried by many people who never develop the disease, which means something else has to tip the balance. For autoimmune rheumatic diseases in general, infections, oxidative stress, and other environmental exposures can alter how immune cells behave, sometimes flipping on inflammatory programs that were previously kept in check. These changes can be epigenetic, meaning they modify gene activity without changing the DNA sequence itself.
The fact that PMR almost exclusively strikes people over 50 also points to aging as a key non-genetic factor. The immune system changes significantly with age, becoming more prone to inflammation and less precise in targeting. This age-related immune shift, layered on top of genetic susceptibility, likely explains why PMR appears late in life even in people who carried the relevant gene variants from birth.
What the HLA-DRB1*04 Variant Means for Treatment
Interestingly, the same genetic variant most strongly linked to PMR susceptibility also influences how the disease behaves. Patients who carry HLA-DRB1*0401 have a higher risk of relapse during treatment and may need higher cumulative doses of corticosteroids during the first year. In one study of Danish patients, those carrying the *04 allele required a median of 4.5 grams of prednisolone in the first year compared to 3.8 grams for those without it. This suggests the variant doesn’t just influence whether you get PMR but also how stubbornly the inflammation persists.
This genetic influence on treatment response is a practical consideration. If you have PMR and find that tapering off steroids triggers flare-ups, your genetic makeup may be part of the explanation. Rapid steroid tapering combined with the HLA-DRB1*0401 variant and persistently elevated inflammatory markers are all recognized risk factors for relapse.
The Bottom Line on Hereditary Risk
PMR has a genetic component, anchored primarily in immune-system genes like HLA-DRB1 and the ANKRD55/IL6ST region. These variants are more common in Northern European populations, which explains the geographic pattern of the disease. But PMR is not hereditary in the way that conditions like sickle cell disease or cystic fibrosis are. There is no evidence that having a parent or sibling with PMR substantially raises your risk, and no familial clustering has been documented for PMR specifically. The condition appears to result from a combination of genetic susceptibility, aging, and environmental triggers that together push the immune system toward the sustained inflammation that defines PMR.